



ASX Announcement

RESULTS OF 2026 ANNUAL STOCKHOLDERS MEETING

8 May 2026 – Melbourne, Australia (**7 May 2026** – Minneapolis, MN United States) – **Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR)** refers to the Annual Stockholders Meeting held today. The results of the meeting are set out in the attached document in accordance with ASX Listing Rule 3.13.2. All resolutions were decided and passed by way of a poll.

Authorised for release by Steve Wedan, Executive Chair, President, and CEO.

ENDS

Media and Investor Relations Contacts

Simon Hinsley
Executive Director, NWR
Email: simon@nwrcommunications.com.au
Mobile: +61 401 909 653

Nick Corkill
VP, Corporate Strategy, Imricor
Email: nick.corkill@imricor.com
Mobile: +61 450 475 633

About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is striving to make interventional medical procedures better, safer, and more cost effective by making it possible for these procedures to be performed under real-time magnetic resonance (MR) imaging guidance, rather than under x-ray fluoroscopy guidance, thus taking advantage of MR's superior imaging capabilities.

Imricor's Products

Imricor is a pioneer and world leader in developing MR-compatible products for cardiac catheter ablation procedures. The Company's products include capital equipment, such as the NorthStar® Mapping System and the Advantage-MR® EP Recorder/Stimulator. Single-use devices include a variety of ablation catheters, diagnostic catheters, steerable sheaths, and other tools used for cardiac ablations.

Imricor's products are approved in the European Union, the Kingdom of Saudi Arabia, and New Zealand. NorthStar is approved in the US.

Foreign Ownership Restrictions

Imricor's CHES Depository Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons excluding qualified institutional buyers (QIBs, as defined in Rule 144A under the Securities Act). However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Results of meeting

Name of entity

Imricor Medical Systems, Inc.

ARBN

633 106 019

Date of meeting

8 May 2026 Australian time (7 May 2026 US time)

Resolutions voted on at the meeting					If decided by poll ⁵					Proxies received ⁶			
Resolution		Result ²	Voting method ³	If s250U applies ⁴	Voted for		Voted against		Abstained	For	Against	Abstain	Discretion ⁹
No ¹	Short description				Number	% ⁷	Number	% ⁸	Number	Number	Number	Number	Number
1	Election of Class I Director – Mr Mark Tibbles	Passed	Poll	N/A	127,124,785	96.79	-	-	4,210,597 (withheld)	127,124,785	-	4,210,597 (withheld)	-
2	Election of Class I Director – Mr Aldo Denti	Passed	Poll	N/A	131,282,559	99.96	-	-	52,823 (withheld)	131,282,559	-	52,823 (withheld)	-
3	Approval of the 2019 Equity Incentive Plan and increase in reserved Shares	Passed	Poll	N/A	101,958,451	81.61	22,923,488	18.35	52,523	101,958,451	22,923,488	52,523	-
4	Grant of Options to Mr Steve Wedan, Chief Executive Officer of the Company	Passed	Poll	N/A	120,624,314	95.97	5,012,822	3.99	51,340	120,624,314	5,012,822	51,340	-
5	Grant of Restricted Stock Award to Mr Peter McGregor, Non-Executive Director of the Company	Passed	Poll	N/A	119,416,095	95.01	6,091,441	4.85	180,940	119,416,095	6,091,441	180,940	-
6	Grant of Restricted Stock Award to Ms Anita Messal, Non-Executive Director of the Company	Passed	Poll	N/A	119,650,249	95.20	5,857,287	4.66	180,940	119,650,249	5,857,287	180,940	-
7	Grant of Restricted Stock Award to Mr Mark Tibbles, Non-Executive Director of the Company	Passed	Poll	N/A	119,654,249	95.20	5,853,287	4.66	180,940	119,654,249	5,853,287	180,940	-
8	Grant of Restricted Stock Award to Mr Aldo Denti,	Passed	Poll	N/A	120,159,057	95.60	5,348,479	4.26	180,940	120,159,057	5,348,479	180,940	-

	Non-Executive Director of the Company												
9	Ratification of the appointment of BDO USA, P.C. as independent registered public accounting firm	Passed	Poll	N/A	131,197,135	99.90	137,424	0.10	823	131,197,135	137,424	823	-

Resolutions proposed but not put to the meeting ¹⁰		
No ¹	Short description	Reason(s) for not putting the resolution to the meeting

Instructions:

1. The resolution numbers in the tables above should match the resolution numbers in the notice of meeting.
2. Insert "Passed" or "Not passed", as appropriate.
3. Insert "Poll" or "Show of hands", as appropriate.
4. Insert "1st strike", "2nd strike" or "N/A", as appropriate.
5. Complete this section if the resolution was decided by a poll. Ignore this section if the resolution was decided by a show of hands.
6. Complete this section for all resolutions, showing the number of valid proxies received and how the proxy was directed to vote on the resolution.
7. Calculate this percentage as the number of votes cast for the resolution, divided by the total number of votes cast on the resolution. When summed with the percentage voted against the resolution, this should add to 100%.
8. Calculate this percentage as the number of votes cast against the resolution, divided by the total number of votes cast on the resolution. When summed with the percentage voted for the resolution, this should add to 100%.
9. "Discretion" means the proxy could vote on the resolution in their discretion.
10. Delete this table if there were no resolutions proposed but not put to the meeting.
11. Add or remove rows from each table to accommodate the number of resolutions proposed in the notice of meeting.
12. Delete these instructions before submitting this form to ASX.
13. See Guidance Note 35 *Security Holder Resolutions* for further guidance.